Menu Search
Equities

Richter Gedeon Vegyeszeti Gyar Nyrt

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RIG2:STU

Richter Gedeon Vegyeszeti Gyar Nyrt

Actions
  • Price (EUR)30.08
  • Today's Change0.08 / 0.27%
  • Shares traded0.00
  • 1 Year change+21.68%
  • Beta0.6054
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.

  • Revenue in HUF (TTM)901.32bn
  • Net income in HUF227.29bn
  • Incorporated1923
  • Employees11.76k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RICHTER:BUD since
announced		Transaction
value
Granata Bio IncDeal completed13 May 202513 May 2025Deal completed8.30%--
Data delayed at least 15 minutes, as of Feb 06 2026 16:07 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.